- Home
- ANEB
as 10-27-2025 9:37am EST
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | LAKEWAY |
| Market Cap: | 111.8M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 25.7K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.80 - $3.42 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Anebulo Pharmaceuticals Inc. News
ANEB Breaking Stock News: Dive into ANEB Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
We're Hopeful That Anebulo Pharmaceuticals (NASDAQ:ANEB) Will Use Its Cash Wisely
Business Wire
5 months ago
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
Simply Wall St.
6 months ago
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Business Wire
8 months ago
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
Simply Wall St.
9 months ago
Anebulo Pharmaceuticals Leads This Trio Of US Penny Stocks
Simply Wall St.
10 months ago
3 US Penny Stocks With Market Caps Under $800M
TipRanks
10 months ago
Anebulo Pharmaceuticals collaborates with FDA to advance selonabant
Business Wire
10 months ago
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
Compare ANEB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ANEB Anebulo Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.